PubMed=8409397; DOI=10.4049/jimmunol.151.8.4209
Schendel D.J., Gansbacher B., Oberneder R., Kriegmair M., Hofstetter A., Riethmuller G., Segurado O.G.
Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
J. Immunol. 151:4209-4220(1993)

PubMed=11175312; DOI=10.1038/sj.gt.3301349
Schendel D.J., Frankenberger B., Jantzer P., Cayeux S., Noessner E., Willimsky G., Maget B., Pohla H., Blankenstein T.
Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.
Gene Ther. 7:2007-2014(2000)

PubMed=11809699
Falk C.S., Noessner E., Weiss E.H., Schendel D.J.
Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Cancer Res. 62:480-487(2002)

PubMed=15755994; DOI=10.1158/1078-0432.CCR-04-1883
Frankenberger B., Pohla H., Noessner E., Willimsky G., Papier B., Pezzutto A., Kopp J., Oberneder R., Blankenstein T., Schendel D.J.
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Clin. Cancer Res. 11:1733-1742(2005)

PubMed=15997395; DOI=10.1007/s00345-005-0505-5
Frankenberger B., Regn S., Geiger C., Noessner E., Falk C.S., Pohla H., Javorovic M., Silberzahn T., Wilde S., Buchner A., Siebels M., Oberneder R., Willimsky G., Pezzutto A., Blankenstein T., Schendel D.J.
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
World J. Urol. 23:166-174(2005)

PubMed=16045799; DOI=10.1186/1479-5876-3-29; PMCID=PMC1188079
Geiger C., Regn S., Weinzierl A., Noessner E., Schendel D.J.
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.
J. Transl. Med. 3:29.1-29.15(2005)

PubMed=16261161; DOI=10.1038/sj.onc.1209188
Djafarzadeh R., Noessner E., Engelmann H., Schendel D.J., Notohamiprodjo M., von Luettichau I., Nelson P.J.
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.
Oncogene 25:1496-1508(2006)